Navigation Links
Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
Date:8/10/2012

CHICAGO, Aug. 10, 2012 /PRNewswire-iReach/ -- Meridian Labs Inc., a Buffalo Grove, IL -based specialty pharmaceutical company, has appointed AmeriTech Advisors healthcare investment banking team to respond to recent interest from healthcare industry members in making a strategic investment in the company as well as merger and acquisition proposals.

Meridian Labs is a specialty pharmaceutical company focusing on the development of cancer treatments through formulation improvements.  The company owns patents on docetaxel and other cancer treatment formulations using the derivatives of beta-cyclodextrin developed through its facilities based in Nanjing, China and Illinois. 

The company's lead product, ML061, is an IP-protected reformulation of Taxotere in Captisol that eliminates Polysorbate 80 and its associated "Black Box" side effects. Meridian intends to gain approval in the US through 5050 (b)(2) submission and will send a pre-IND meeting request to the FDA to on the submission in teh coming weeks. .

Strategic alternatives the Company may pursue could include strategic investment or other collaboration agreements, a merger, an equity or debt financing, or sale of the Company. The Company does not intend to disclose developments with respect to this process until the evaluation of strategic alternatives has been completed and the board of directors has approved a specific transaction. 

About Meridian Labs

 As the company's leading product, ML061 improves the formulation of Taxotere for cancer treatment, based on the same active ingredient docetaxel with a novel delivery method.  By avoiding polysorbate 80 and ethanol, our objective is to show that ML061 improves the safety profile of Taxotere while maintaining its efficacy. We plan to bring the product to market as the top choice of chemotherapy for various cancer indications.

About AmeriTech Advisors

AmeriTech is an investment bank dedicated to providing capital raising and strategic advisory services to emerging growth companies in the technology and medtech sectors with market capitalizations of between $25 million and $500 million. Their bankers have 20 years' experience at major global investment banks and as senior managers at public companies with experience executing successful transactions. Their goal is to build mutually beneficial relationships between our emerging growth company clients, technology and medtech/pharma partners, and their network of investors

Media Contact: william zhao, Meridian Lab, 847-275-5923, lily.tan@meridian-lab.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Meridian Lab
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millstone Medical Outsourcing Hires New Vice President Quality
2. NHD Hires Ron Cronin as Executive Director
3. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
4. Health Revenue Assurance Associates Hires Valerie Rinkle as Vice President of Revenue Integrity Informatics
5. Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc
6. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
7. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
8. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
9. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
10. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
11. Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):